JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) financials

JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]

Market Cap: ₹1,440Cr.
Current Price: ₹218
Stock P/E: 30.6
ROE: 17.3%
ROCE: 22.7%
Book Value: ₹41.2
Dividend Yield: 1.83%
52W High / Low: ₹265/155

In Jun 2026, JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) reported sales ₹82 Cr and net profit ₹13 Cr.

Annual TTM: sales ₹294 Cr, net profit ₹45 Cr.

Shareholding: Promoters 69.06% (Jun 2026), FIIs 2.30% (Jun 2026), DIIs 0.62% (Jun 2026), Public 28.04% (Jun 2026), No. of Shareholders 24,181% (Jun 2026).

JAGSNPHARM quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	75	74	59	76	74	73	64	82
Expenses	58	58	50	61	58	57	53	65
Operating Profit	16	16	9	14	16	16	11	17
OPM %	22%	21%	15%	19%	22%	22%	17%	21%
Other Income	2	26	3	3	3	1	3	3
Interest	0	0	0	0	0	0	0	0
Depreciation	2	2	2	2	2	2	2	2
Profit before tax	15	39	9	14	17	15	12	18
Tax %	25%	17%	24%	25%	25%	25%	25%	25%
Net Profit	11	32	7	11	13	11	9	13
EPS in Rs	1.73	4.82	0.99	1.62	1.89	1.64	1.31	2.00
Raw PDF	—	—	—	—	—	—	—	—

JAGSNPHARM profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	159	188	218	237	209	269	287	294
Expenses	150	169	192	203	186	218	229	233
Operating Profit	9	19	26	34	23	51	58	61
OPM %	5%	10%	12%	14%	11%	19%	20%	21%
Other Income	3	4	3	2	9	28	10	10
Interest	1	1	0	0	1	1	1	1
Depreciation	1	1	2	1	2	8	9	9
Profit before tax	9	22	27	35	30	70	58	61
Tax %	16%	22%	29%	23%	25%	21%	25%	—
Net Profit	8	17	19	27	22	55	43	45
EPS in Rs	1.20	2.60	2.88	4.08	3.40	8.34	6.43	6.84
Dividend Payout %	17%	15%	56%	49%	59%	30%	62%	—

JAGSNPHARM balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	13	13	13	13	13	13	13
Reserves	91	98	109	120	146	174	227	263
Borrowings	4	5	7	0	6	9	9	8
Other Liabilities	28	31	35	31	30	21	29	32
Total Liabilities	136	147	164	164	195	217	278	317
Fixed Assets	22	22	26	23	24	9	94	85
CWIP	4	4	0	0	0	0	0	0
Investments	0	11	15	51	1	0	0	0
Other Assets	110	109	123	91	170	208	184	231
Total Assets	136	147	164	164	195	217	278	317

JAGSNPHARM cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	31	11	28	7	47	35	55	47
Cash from Investing Activity	-1	-11	-2	-26	-58	-25	-45	-36
Cash from Financing Activity	-6	-1	-7	-18	-0	-9	-12	-12
Net Cash Flow	24	-0	19	-36	-11	2	-2	-1
Free Cash Flow	30	12	28	6	48	35	90	47
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	311%	150%	164%	54%	158%	189%	124%	101%

JAGSNPHARM shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	67.98%	67.82%	67.77%	67.65%	67.54%	67.39%	67.89%	69.06%
FIIs	2.30%	2.10%	2.10%	2.17%	2.12%	2.12%	2.44%	2.30%
DIIs	0.11%	0.00%	0.00%	0.05%	0.08%	0.15%	0.22%	0.62%
Public	29.63%	30.10%	30.11%	30.12%	30.25%	30.34%	29.44%	28.04%
No. of Shareholders	15,633	18,471	21,085	22,899	24,653	24,895	26,264	24,181

JAGSNPHARM key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	45	49	25	26	32	19	18	22
Inventory Days	164	191	134	122	82	68	58	51
Days Payable	59	76	82	76	66	35	37	40
Cash Conversion Cycle	150	164	77	72	48	53	39	33
Working Capital Days	67	55	32	59	34	52	9	11
ROCE %	9%	9%	18%	20%	25%	17%	23%	23%

JAGSNPHARMUpdated 18 Oct 2026, 18:00

Jagsonpal Pharmaceuticals

JAGSNPHARMUpdated 18 Oct 2026, 18:00

Market Cap

₹1,440Cr.

Current Price

₹218

High / Low

₹265/155

Stock P/E

30.6

ROE17.3%

ROCE22.7%

Book Value₹41.2

Face Value₹2.00

Dividend Yield1.83%

About

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	60	52	2	0	10	26	7	1.14
Sep 2023	58	49	2	0	10	25	7	1.14
Dec 2023	47	44	3	0	5	25	4	0.6
Mar 2024	43	41	2	0	5	22	4	0.54
Jun 2024	61	51	-2	1	7	25	5	0.81
Sep 2024	75	58	2	2	15	25	11	1.73
Dec 2024	74	58	26	2	39	17	32	4.82
Mar 2025	59	50	3	2	9	24	7	0.99
Jun 2025	76	61	3	2	14	25	11	1.62
Sep 2025	74	58	3	2	17	25	13	1.89
Dec 2025	73	57	1	2	15	25	11	1.64
Mar 2026	64	53	3	2	12	25	9	1.31
Jun 2026	82	65	3	2	18	25	13	2

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	138	4	129	0	3	2	30	1	0.18
Mar 2016	143	5	132	1	3	4	20	3	0.5
Mar 2017	144	3	138	13	2	14	18	12	1.81
Mar 2018	127	1	138	0	0	-12	-1	-12	-1.76
Mar 2019	167	1	157	1	1	9	20	7	1.1
Mar 2020	159	1	150	3	1	9	16	8	1.2
Mar 2021	188	1	169	4	1	22	22	17	2.6
Mar 2022	218	0	192	3	2	27	29	19	2.88
Mar 2023	237	0	203	2	1	35	23	27	4.08
Mar 2024	209	1	186	9	2	30	25	22	3.4
Mar 2025	269	1	218	28	8	70	21	55	8.34
Mar 2026	287	1	229	10	9	58	25	43	6.43
TTM	294	1	233	10	9	61	—	45	6.84

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	69.06%
FIIs	2.3%
DIIs	0.62%
Public	28.04%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	68.72%	0.38%	0.82%	30.07%
Dec 2023	68.48%	0.53%	0.82%	30.16%
Mar 2024	68.09%	0.73%	0.84%	30.33%
Jun 2024	68.04%	1.1%	0.84%	30.01%
Sep 2024	67.98%	2.3%	0.11%	29.63%
Dec 2024	67.82%	2.1%	0%	30.1%
Mar 2025	67.77%	2.1%	0%	30.11%
Jun 2025	67.65%	2.17%	0.05%	30.12%
Sep 2025	67.54%	2.12%	0.08%	30.25%
Dec 2025	67.39%	2.12%	0.15%	30.34%
Mar 2026	67.89%	2.44%	0.22%	29.44%
Jun 2026	69.06%	2.3%	0.62%	28.04%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	13	82	39	19	154	52	0	0	102	154
Mar 2016	13	85	38	22	159	52	0	0	108	159
Mar 2017	13	97	8	25	143	22	0	0	121	143
Mar 2018	13	85	8	23	130	21	3	0	105	130
Mar 2019	13	91	4	28	136	22	4	0	110	136
Mar 2020	13	98	5	31	147	22	4	11	109	147
Mar 2021	13	109	7	35	164	26	0	15	123	164
Mar 2022	13	120	0	31	164	23	0	51	91	164
Mar 2023	13	146	6	30	195	24	0	1	170	195
Mar 2024	13	174	9	21	217	9	0	0	208	217
Mar 2025	13	227	9	29	278	94	0	0	184	278
Mar 2026	13	263	8	32	317	85	0	0	231	317

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	4	0	-1	2
Mar 2016	9	-2	-6	1
Mar 2017	-3	41	-34	5
Mar 2018	-2	-3	-1	-6
Mar 2019	31	-1	-6	24
Mar 2020	11	-11	-1	0
Mar 2021	28	-2	-7	19
Mar 2022	7	-26	-18	-36
Mar 2023	47	-58	0	-11
Mar 2024	35	-25	-9	2
Mar 2025	55	-45	-12	-2
Mar 2026	47	-36	-12	-1

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	119	106	100	73	45	49	25	26	32	19	18	22
Inventory Days	176	246	295	307	164	191	134	122	82	68	58	51
Days Payable	42	60	56	54	59	76	82	76	66	35	37	40
Cash Conversion Cycle	252	292	339	325	150	164	77	72	48	53	39	33
Working Capital Days	68	72	154	149	67	55	32	59	34	52	9	11
ROCE %	5%	7%	3%	-10%	9%	9%	18%	20%	25%	17%	23%	23%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of JAGSONPAL PHARMACEUTICALS (JAGSNPHARM)?

The reported market capitalisation for JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) is ₹1,440Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of JAGSNPHARM?

The current price shown for JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) on Fincrux is ₹218 with a 52-week high/low of ₹265/155.

What is the P/E ratio of JAGSONPAL PHARMACEUTICALS (JAGSNPHARM)?

The stock P/E for JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) is 30.6 on Fincrux, with ROE at 17.3% and ROCE at 22.7%.

What were JAGSNPHARM latest quarterly results?

For Jun 2026, JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) reported sales ₹82 Cr and net profit ₹13 Cr (figures in ₹ crore unless noted).

What are JAGSNPHARM annual sales and net profit?

For TTM, JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) shows sales of ₹294 Cr and net profit of ₹45 Cr on the Fincrux profit & loss statement.

Who owns JAGSONPAL PHARMACEUTICALS (JAGSNPHARM)?

Latest shareholding for JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) on Fincrux: Promoters 69.06% (Jun 2026), FIIs 2.30% (Jun 2026), DIIs 0.62% (Jun 2026), Public 28.04% (Jun 2026), No. of Shareholders 24,181% (Jun 2026).

Where can I find JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) financials?

JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show JAGSNPHARM balance sheet and cash flow?

Yes. The JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 18:00